Virtu Financial’s Y-mAbs Therapeutics YMAB Stock Holding History

Virtu Financial’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,147	Closed	-$126K	–	2119
2023 Q1	$126K	Buy	+25,147	New	+$103K	0.01%	901

Other funds holding YMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Virtu Financial's YMAB Position: Q2 2023 in Review

Virtu Financial sold out of Y-mAbs Therapeutics (YMAB) in Q2 2023, closing a stake of 25,147 shares — an estimated $126K sold.

Virtu Financial first reported a position in YMAB in Q1 2023 and held it in 1 quarter. The position peaked at $126K in Q1 2023. 95 funds tracked by Wall St. Rank hold YMAB as of Q2 2023.

Virtu Financial reported no remaining Y-mAbs Therapeutics position as of Q2 2023 after selling out during the quarter.
Virtu Financial sold 25,147 Y-mAbs Therapeutics shares in Q2 2023, an estimated $126K.
Virtu Financial first reported a position in Y-mAbs Therapeutics in Q1 2023 and held it in 1 quarter.
Virtu Financial's Y-mAbs Therapeutics position peaked at $126K in Q1 2023.
95 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2023.

Based on Virtu Financial's 13F filing for Q2 2023, filed 27 Jul 2023.